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Abstract
Haematological malignancies induce important alterations of the immune system, which account for the high frequency 
of autoimmune complications observed in patients. Cutaneous immune-mediated diseases associated with haematological 
malignancies encompass a heterogeneous group of dermatoses, including, among others, neutrophilic and eosinophilic 
dermatoses, autoantibody-mediated skin diseases, vasculitis and granulomatous dermatoses. Some of these diseases, such 
as paraneoplastic pemphigus, are associated with an increased risk of death; others, such as eosinophilic dermatoses of hae-
matological malignancies, run a benign clinical course but portend a significant negative impairment on a patient’s quality 
of life. In rare cases, the skin eruption reflects immunological alterations associated with an unfavourable prognosis of the 
associated haematological disorder. Therapeutic management of immune-mediated skin diseases in patients with haemato-
logical malignancies is often challenging. Systemic corticosteroids and immunosuppressive drugs are considered frontline 
therapies but may considerably augment the risk of serious infections. Indeed, developing a specific targeted therapeutic 
approach is of crucial importance for this particularly fragile patient population. This review provides an up-to-date over-
view on the immune-mediated skin diseases most frequently encountered by patients with onco-haematological disorders, 
discussing new pathogenic advances and therapeutic options on the horizon.
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cell lineage origin, they are divided into myeloid and lym-
phoid neoplasms. Each group includes tumours with aggres-
sive or indolent biological behaviour, that in turn results in 
an acute or chronic clinical course and a different prognosis 
[1, 2]. B-cell chronic lymphatic leukaemia is by far the most 
common form, with a reported incidence of approximately 
5.1/100,000 new cases per year in Western populations [3].
Patients with HMs can experience a broad range of der-
matological manifestations. Comorbid diseases affecting the 
skin are often associated with a significant impairment on 
the quality of life and, more rarely, with an increased risk of 
death [4–6]. Dermatological manifestations associated with 
HMs can be divided into specific and non-specific. Specific 
manifestations include the massive infiltration of the skin by 
neoplastic cells, referred to as leukaemia cutis. Non-specific 
manifestations include: (i) dermatological changes second-
ary to bone marrow failure, e.g. pallor and ecchymosis; (ii) 
skin infections; (iii) adverse reactions to anti-neoplastic 
drugs; and (iv) immune-mediated diseases [4, 5].
Haematological malignancies can trigger both innate and 
acquired immune-mediated skin diseases. Various mecha-
nisms can be involved and possibly synergise in driving the 
immune reaction (Table 1). First, in patients with HMs, both 
1  Haematological Malignancies as a Trigger 
for Skin Autoimmunity
Haematological malignancies (HMs) account for a highly 
heterogeneous group of neoplastic disorders. Based on the 
 R. Maglie et al.
Key Points 
Several immune-mediated diseases of the skin have been 
shown to occur in patients with haematological malig-
nancies.
Treatment of these dermatoses is often challenging and 
mostly relies on the use of systemic corticosteroids and 
immunosuppressive drugs.
Improved understanding of the mechanisms by which 
neoplastic cells drive the emergence of these dermatoses 
can lead to new targeted therapies that can eventually 
improve a patient’s outcome.
when a naïve self-reactive T cell escapes from the negative 
selection in the thymus, this usually becomes anergic if it 
does not encounter an antigen-presenting cell offering suf-
ficient co-stimulatory signals. Interestingly, neoplastic cells 
from B-cell chronic lymphatic leukaemia and non-Hodgkin 
lymphomas can serve as excellent antigen-presenting cells, 
owing to up-regulation of class I and II major histocompat-
ibility molecules, β2 microglobulin and co-stimulatory mol-
ecules, such as B7. Collectively, these molecules promote 
expansion and differentiation of naïve T cells into effector 
cells [7, 8]. As a means to evade the immune surveillance, 
HM are able to recruit and activate interleukin (IL)-10-pro-
ducing T-regulatory (T-reg) cells. Although this mecha-
nism would in theory prevent autoimmunity phenomena, a 
recent study on chronic lymphatic leukaemia demonstrated 
that activated T-reg cells are also able to produce IL-4 and 
IL-17, suggesting they may promote both tolerance against 
the tumour and inflammation in the periphery [9]. It is also 
remarkable that T-reg cells are more susceptible compared 
with other T-cell subsets to the effects of chemotherapeutic 
agents, such as fludarabine [7].
There is compelling evidence that neoplastic B cells can 
recognise various antigens, either foreign antigens or self-
antigens. Antigen-dependent stimulation of the B-cell recep-
tor represents a fundamental mechanism that perpetuates 
B-cell proliferation. In parallel, some neoplastic B cells can 
still preserve the ability to produce antibodies against the 
recognised antigen, behaviour that may lead to autoantibody-
mediated diseases [10]. Direct production of anti-keratino-
cyte antigens by tumour cells has been shown to occur in 
patients with PNP associated with Castleman’s disease [11].
Development of haematological tumours is associated 
with profound changes in the balance between various T-cell 
compartments and cytokine deregulation. Remarkably, 
Table 1  Mechanisms involved in the pathogenesis of immune-mediated skin diseases in patients with haematological malignancies
Th T helper cell, T-reg T-regulatory cell
Mechanism Haematological tumour
Defective central T-cell tolerance (escape of immature and autoreactive  
T cells from the negative selection in the thymus)
Lymphoid malignancies
Defective peripheral T-cell tolerance (efficient costimulatory signals to 
self-reactive T cells by neoplastic cells; defective T-reg function)
Myeloid and lymphoid malignancies
Production of autoantibodies by neoplastic cells B-cell lymphoproliferative disorders
Th1/Th2 cell imbalance Acute myeloid leukaemia, B-cell chronic lymphatic leukaemia, 
Hodgkin’s lymphoma, cutaneous T-cell lymphomas, chronic 
myeloid leukaemia
Increased Th17 cell activity Hodgkin’s and non-Hodgkin’s lymphomas, acute leukaemia, B-cell 
chronic lymphatic leukaemia
Cytokine deregulation Myeloid and lymphoid malignancies
Haematological treatments, including allogenic stem cell transplantation 
and immune checkpoint inhibitors (not extensively discussed in the 
present review)
Myeloid and lymphoid malignancies
central and peripheral T-cell tolerance might be impaired. 
Central T-cell tolerance is regulated by the thymus through 
negative selection of self-reactive T cells. A paradigmatic 
example of altered negative selection in the thymus induced 
by malignancies occurs in patients with thymoma, which 
is often accompanied by autoimmune manifestations. It is 
interesting to note that both thymoma and HMs, with spe-
cial regard to lymphoproliferative disorders, induce a simi-
lar profile of autoimmune diseases, such as paraneoplastic 
pemphigus (PNP). It is thus arguable that HMs may favour 
the emergence of autoreactive T-cell clones that escape or 
bypass negative selection in the thymus, although there is no 
evidence that this is related to a direct invasion of the thymus 
by malignant cells [7].
Peripheral T-cell tolerance involves a complex immuno-
logic mechanism that prevents autoreactive T cells to be acti-
vated in peripheral tissues and cause pathology. Specifically, 
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single nucleotide polymorphisms in several T helper-1/T 
helper-2 (Th1/Th2) cytokine genes have been associated 
with an increased risk of non-Hodgkin’s lymphomas [12]. In 
patients with acute myeloid leukaemia, chronic myeloid leu-
kaemia and B-cell chronic lymphatic leukaemia, there is an 
increase in the Th2/Th1 ratio that is further augmented dur-
ing disease progression and in refractory patients [13–15]. 
Likewise, a shift towards a Th2-type response is observed 
in patients with Hodgkin’s lymphoma and cutaneous T-cell 
lymphomas [16]. Hyperactivation of Th2 cells may be 
responsible for eosinophil recruitment in the skin in eosino-
philic dermatosis of haematologic malignancies (EDHM), 
and for stimulating autoantibody production in HM-associ-
ated autoimmune bullous dermatoses. In contrast, studies 
on chronic myelogenous leukaemia demonstrated increased 
levels of IL-1 and IL-6, which have been shown to be cru-
cial molecules involved in the pathogenesis of neutrophilic 
dermatosis [17, 18]. Furthermore, serum levels of IL-17 are 
elevated in patients with acute myeloid and lymphoid leu-
kaemia compared with healthy donors [19, 20]; similarly, 
growth and expansion of neoplastic cells in Hodgkin’s 
lymphoma and B-cell chronic lymphocytic leukaemia are 
associated with a tumour microenvironment enriched in T 
helper-17 cells [21, 22]. These cells likely play an important 
role in several diseases of the skin, including neutrophilic 
dermatoses and autoimmune bullous dermatoses.
Finally, it should be considered that the emergence of 
immune-mediated skin diseases can be the consequence of 
haematological treatments. Examples are patients undergo-
ing allogenic stem cell transplantation, experiencing ‘graft 
vs host disease’ or those treated with immune checkpoint 
inhibitors, the latter being associated with an increased risk 
of developing autoimmune bullous skin diseases, such as 
bullous pemphigoid (BP) [23, 24].
Based on these findings, it is arguable that the risk of 
developing an immune-mediated disease of the skin in asso-
ciation with an HM depends on several factors, including 
genetic and epigenetic factors, the subtype of HM and the 
impact of the particular treatments [25]. This review pro-
vides an up-to-date overview on the main immune-mediated 
skin diseases associated with HMs. We show that HMs can 
induce different prototypes of skin inflammation, including 
neutrophilic and eosinophilic dermatoses and autoantibody-
mediated and T-cell-dependent skin diseases.
2  Neutrophilic Dermatoses
Neutrophilic dermatoses (NDs) are a heterogenous group 
of disorders hallmarked clinically by polymorphic lesions 
and histologically by neutrophil-rich tissue infiltrates [26]. 
Although the pathomechanisms involved in these condi-
tions remain still incompletely defined, an overexpression 
of proinflammatory cytokines, such as IL-1, IL-8, IL-17 
and tumour necrosis factor-α, which amplify neutrophil 
recruitment and accumulation in the skin, is regarded as 
the primum movens in the pathophysiological scenario [27, 
28]. Neutrophilic dermatoses are currently regarded as poly-
genic autoinflammatory conditions based on the fact that 
they share mutations with classic autoinflammatory dis-
eases, which encompass a spectrum of forms characterised 
by sterile neutrophil-driven inflammation in the affected 
organs and are due to mutations involving genes regulating 
the innate immunity [29–31]. The autoinflammatory para-
digm is further supported by studies on mouse models of ND 
[32–36]. Although innate immunity dysfunction is pivotal in 
the pathogenesis of NDs, the contributing role of adaptive 
immunity is currently recognised [37–39], mainly based on 
an overexpression of Th1-related cytokines in the lesional 
skin of pyoderma gangrenosum (PG) [39].
The association between NDs and HMs is widely 
acknowledged. The onset of the HM may follow, precede 
or be concomitant with the diagnosis of ND [40]. Neutro-
philic dermatoses most commonly associated with HMs are: 
(i) PG; (ii) Sweet syndrome (SS); (iii) erythema elevatum 
diutinum; (iv) subcorneal pustular dermatosis; and (v) neu-
trophilic eccrine hidradenitis (Fig. 1) [41]. Beyond these 
entities, other NDs such as neutrophilic panniculitis and 
immunoglobulin A (IgA) pemphigus [42–44] have been 
more rarely reported to arise in the context of HMs. Over-
lap/transitional forms between the different entities as well 
as extracutaneous localisations have also been reported in 
association with underlying HMs [45].
Myeloid malignancies, such as acute myeloid leukaemia, 
chronic myeloproliferative neoplasms, myeloproliferative 
syndromes and myelomonocytic leukaemia, are the HMs 
most frequently associated with NDs [46], followed by mon-
oclonal gammopathies and multiple myeloma [47, 48], and, 
less frequently, chronic or acute lymphoid neoplasms [49, 
50]. Increasing evidence indicates that in myeloid neoplasm-
associated NDs, skin-infiltrating neutrophils may be clonally 
related to the neoplastic cells and may have differentiated 
from them [51–53].
In monoclonal gammopathy-associated NDs, the mono-
clonal immunoglobulin itself does not seem to be directly 
responsible for the cutaneous manifestations, while a pecu-
liar inflammatory profile with increased rates of cytokines 
such as IL-6, vascular endothelial growth factor, epidermal 
growth factor, intercellular adhesion molecule-1, granu-
locyte-colony stimulating factor and monocyte chemoat-
tractant protein-1 have been postulated to be either the 
cause or the consequence of skin symptoms [47]. This is 
particularly true for paraneoplastic SS, which has been fre-
quently described as associated with high levels of cytokines 
such as granulocyte-colony stimulating factor, IL-4, IL-6 
and interferon-γ, some of which have been reported to be 
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produced by neoplastic cells [54–57]. However, malignancy-
associated SS has been also hypothesised to be a hypersen-
sitivity reaction to tumour antigens [58]. Finally, NDs, espe-
cially SS but also PG and neutrophilic eccrine hidradenitis, 
may be induced by drugs, such as azacytidine [59], imatinib 
[60], lenalidomide and granulocyte-colony stimulating fac-
tor [61, 62], used for the treatment of HMs or related condi-
tions [63, 64].
2.1  Pyoderma Gangrenosum
Pyoderma gangrenosum is a rare inflammatory ND charac-
terised clinically by ulcers with undermined erythematous-
violaceous edges (Fig. 1a), and histologically by neutro-
phil-rich infiltrates. In a retrospective cohort study on 313 
patients, Langan et al. reported that haematological disor-
ders had a prevalence of 3.9% [65]. In a systematic review 
published in 2015 including 823 cases of PG, HMs have 
been found to be associated with this condition in 12.5% of 
patients, following inflammatory bowel diseases (n = 537; 
65.2%) and polyarthritis (n = 133; 16.1%) [66]. Haemato-
logical malignancies associated with PG, which are a major 
cause of death in this disease [41, 67], are mainly repre-
sented by acute and chronic myeloid leukaemia [68, 69], 
myelodysplastic syndrome [70], multiple myeloma [71], 
monoclonal gammopathy of undetermined significance [72] 
and lymphoma [73]. Although IgG isotype gammopathies 
are overall more frequent, most monoclonal gammopathies 
associated with PG are of the IgA isotype [47, 74].
In a recent systematic review of 340 cases of HM-asso-
ciated PG [74], the most frequently observed neoplasm 
was myelodysplastic syndrome (n = 83; 24.4%), followed 
by monoclonal gammopathy of undetermined significance 
(n = 75; 22.1%) and acute myeloid leukaemia (n = 39; 
11.5%). In the same systematic review, classic (ulcerative) 
PG was the most common presentation, while the bullous 
Fig. 1  Spectrum of neutrophilic dermatoses: a pyoderma gangrenosum; b Sweet syndrome; c erythema elevatum diutinum; and d subcorneal 
pustular dermatosis
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variant represented the most frequent form observed in the 
subgroup with acute myeloid leukaemia [74].
This is in contrast to the findings of Bennett et al., who 
concluded in a study of 86 patients that haematological dis-
eases or malignancies were associated with BP more fre-
quently than with classic PG [75]. The systematic review 
by Montagnon et al. [74] showed also that the diagnosis 
of HMs preceded the onset of PG in most cases and that 
most patients with available data (75%) achieved PG control 
with systemic corticosteroids, while chemotherapy alone led 
to healing of PG in only 7.5% of cases. Cyclosporine and 
TNF-α inhibitors are not recommended in patients with HM-
associated PG [41].
2.2  Sweet Syndrome
It is acknowledged that SS, a rare skin disease character-
ised by painful erythematous plaques (Fig. 1b) showing a 
neutrophilic dermal infiltrate and associated with fever and 
neutrophilia, is associated with HMs, mostly acute myeloid 
leukaemia [76, 77] but also myelodysplastic syndrome 
[78], with a prevalence range of 15–27% according to case 
series [79, 80]. Chronic myeloid leukaemia, B-cell chronic 
lymphatic leukaemia, monoclonal gammopathies (mainly 
immunoglobulin G [IgG] type) and multiple myeloma have 
also been described as associated with SS. Cutaneous mani-
festations typically occur months to years before the HM 
diagnosis (but may also be concomitant with the onset of the 
HM) and recur after clinical remission during haematologi-
cal relapses [79]. Idiopathic SS and HM-associated SS share 
common clinical features, being atypical variants, such as 
bullous or ulcerated SS, equally frequent in the two forms 
[81]. However, rare cases of SS presenting with widespread, 
giant cellulitis-like features have been described mainly in 
association with HMs [82, 83]. Response to treatment and 
the rate of recurrences are also similar [81]. Histiocytoid 
SS is a variant of this disease clinically similar to ‘classic’ 
SS and histopathopathologically characterised by a dermal 
infiltrate rich in immature myelomonocytic cells with histio-
cytoid morphology [84]. This variant has been demonstrated 
to be more frequent in patients with HMs, in particular those 
with myelodysplastic syndrome [85]. Therapy of HM-asso-
ciated SS mainly relies on systemic corticosteroids and con-
trol of the underlying HM. The onset of SS in the context of 
HMs is not a factor of poor prognosis [86].
2.3  Erythema Elevatum Diutinum
Erythema elevatum diutinum, a chronic localised form 
of leukocytoclastic vasculitis typically presenting with 
red-to-violaceous papules, nodules or plaques on the exten-
sor surfaces of the limbs [87] (Fig. 1c), has been reported 
as occurring in the context of a wide range of HMs, mainly 
represented by monoclonal gammopathies, particularly of 
the IgA isotype [88, 89], and myelodysplastic syndrome 
[90]. Other HMs more rarely described as associated with 
erythema elevatum diutinum are multiple myeloma [91], 
B-cell chronic lymphatic leukaemia [92], chronic myeloid 
leukaemia [93] and non-Hodgkin’s lymphoma [89, 94]. 
Dermatologic manifestations usually precede the onset of 
the HM by years [89]. First-line treatment is represented by 
oral dapsone.
2.4  Subcorneal Pustular Dermatosis
Subcorneal pustular dermatosis is a rare chronic-relapsing 
pustular eruption characterised by subcorneal flaccid pus-
tules that contain neutrophils on histopathology (Fig. 1d) 
[95]. It may be associated with monoclonal gammopathies, 
most often of the IgA isotype, which represent the most 
common associated HM [96, 97]. Haematological malignan-
cies less frequently reported as related to subcorneal pustular 
dermatosis are IgA myeloma [98], aplastic anaemia [99], 
lymphomas [100] and chronic lymphocytic leukaemia [101]. 
Cutaneous signs may appear years before the diagnosis of 
the HM and may improve with the treatment of the underly-
ing neoplasm [95]. Oral dapsone remains the mainstay of 
treatment, while topical corticosteroids, phototherapy, oral 
corticosteroids and acitretin are second-line therapies [95].
2.5  Neutrophil Eccrine Hidradenitis
Neutrophil eccrine hidradenitis is a rare neutrophilic der-
matosis characterised clinically by infiltrated or edematous 
SS-like papules or plaques and histologically by aseptic 
neutrophilic infiltrates localised around eccrine coils and 
glands; the lesions are asymptomatic, pruritic or pain-
ful, and develop on the trunk, face or extremities [102]. 
In a literature review of 51 cases, 67% had acute myeloid 
leukaemia and had received chemotherapy [102]. Other 
associated haematological neoplasms were B-cell chronic 
lymphatic leukaemia, chronic myelomonocytic leukaemia, 
Hodgkin’s lymphoma and non-Hodgkin’s lymphoma [102]. 
Most patients (84%) had been treated with chemotherapy 
(particularly cytarabine and anthracyclines) before the onset 
of neutrophil eccrine hidradenitis [102]. Associated fever, 
which is frequent, may be in most cases related to neutrope-
nia. Generally, patients with neutrophil eccrine hidradenitis 
exhibit a self-resolving course within a few days or weeks 
and no specific treatment is required [102].
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3  Eosinophilic Dermatoses and Related Skin 
Manifestations
3.1  Eosinophilic Dermatoses of Haematological 
Malignancies
Eosinophilic dermatoses of HMs encompass a heterogene-
ous group of cutaneous eruptions that predominantly occur 
in patients with indolent lymphoproliferative disorders, 
mostly B-cell chronic lymphatic leukaemia [103]. The con-
dition was first described by Weed in 1965, reporting on ten 
patients with B-cell chronic lymphatic leukaemia experienc-
ing unusual delayed hypersensitivity reactions to mosquito 
bites [104]. Until then, several other authors had reported 
similar clinical manifestations, collectively referred to as 
“insect bite-like reactions”, in patients with haematological 
disorders without a clear history of insect bites [105, 106]. 
The term EDHM can be viewed as an umbrella concept, as 
these cutaneous eruptions show non-specific clinical find-
ings but share the presence of eosinophil-enriched inflamma-
tory infiltrates on histopathology. The diagnosis is straight-
forward when other causes of tissue eosinophilia (e.g. drug 
reactions, scabies and BP) have been excluded [107].
Besides B-cell chronic lymphatic leukaemia, where 
EDHM is estimated to affect 6–8% of patients, and B-cell 
lymphoproliferative disorders, EDHM can also occur in 
association with other HMs, such as T-cell lymphomas, 
acute leukaemia, chronic myeloproliferative disorders and 
plasma cell dyscrasias [103, 105, 108, 109]. The disease 
usually manifests months to years after the diagnosis of the 
HM; however, a minority of patients experienced the skin 
eruption up to 10 years prior to the haematological diag-
nosis [105, 110]. This is a particularly interesting finding 
because it raises questions as to whether patients affected 
by ‘idiopathic’ eosinophilic dermatoses should be monitored 
closely because of the risk of developing a lymphoprolif-
erative disorder. There are contrasting data regarding the 
association of EDHM with the clinical course of the HM. 
Large case series failed to identify correlations between skin 
lesion onset or recurrence and HM activity [103, 105, 110]. 
Isolated case reports conversely described the occurrence or 
worsening of EDHM during phases of high tumour burden 
or transition from indolent to aggressive forms [111]. A lack 
of prospective studies means it is still uncertain whether 
patients with haematological disorders with EDHM have 
a different prognosis compared to patients without EDHM.
On clinical examination, EDHM presents with papules, 
vesicles, blisters, plaques or nodules that characteristically 
develop on an erythematous urticarial background. The 
eruption is often widespread and can affect both photo- 
and non-photo-exposed areas. Patients always experience 
intense and often intolerable pruritus. Revision of the 
published cases allows the identification of at least three 
main clinical patterns: (i) a bullous pattern, characterised 
by a predominance of vesiculobullous lesions closely 
resembling BP (Fig. 2a); (ii) an insect-bite like pattern, 
characterised by discrete urticarial papules sometimes 
with overwhelming vesicles resembling papular urticaria 
(Fig. 2b); and (iii) a cellulitis-like pattern, characterised 
by thick urticarial plaques or nodules resembling Wells 
syndrome (Fig. 2c) [112]. In all the cases, histopathology 
indicates a variably dense, inflammatory dermal infiltrate 
with a predominance of lymphocytes and eosinophils. 
Sometimes, flame figures are visible (Fig. 3a, b) [103, 
112]. Additional histopathologic features include dermal 
oedema, dermal-epidermal detachment, eosinophilic 
spongiosis and parakeratosis [113]. In patients presenting 
with blisters and histological evidence of dermal-epidermal 
detachment, direct immunofluorescence of perilesional 
skin or serum tests usually fail to identify autoantibodies 
against BP180 or other proteins of the dermal–epidermal 
Fig. 2  Main clinical pattern of eosinophilic dermatosis of haematological malignancies: a bullous pemphigoid-like pattern; b insect bite-like 
pattern; and c eosinophilic cellulitis-like pattern
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junction [114]. This means EDHM can be distinguished 
from BP or other subepidermal autoimmune bullous 
disorders. In Asian countries, a distinct presentation of 
EDHM includes “eosinophilic pustular folliculitis of HM”. 
It features pruritic, reddish, sterile, follicular papules and 
pustules; microscopic examination shows an inflammatory 
infiltrate consisting of lymphocytes and eosinophils 
around the hair follicles and sebaceous glands, similar to 
Ofuji disease [115, 116]. Another presentation of EDHM 
resembling varicella zoster infection has also been reported 
[117].
The pathogenesis of EDHM is far less clear to date. 
Many patients refer to a temporal association between the 
manifestation of EDHM and mosquito bites. Interestingly, 
experimental studies indicate that mosquito salivary gland 
extracts activate T-cell proliferation and the release of IL-5 
in patients with Wells syndrome [118, 119]. Considering 
the clinical overlap between Wells syndrome and EDHM, it 
would be reasonable to think that a similar mechanism may 
work also for EDHM. Other authors believe that chemother-
apeutics may serve as a trigger for EDHM [105]. However, 
evidence for a direct association between EDHM and drugs 
comes only from a study by Rossini et al., describing three 
patients with hairy cell leukaemia treated with cladribine 
[120].
One of the most intriguing debates concerns the role of 
leukaemic cells in EDHM. Many studies of patients with 
B-cell chronic lymphatic leukaemia with EDHM dem-
onstrated the presence of neoplastic B cells within the 
inflammatory infiltrate of the skin lesions [110, 113, 121]. 
However, this is not a specific finding of EDHM, as these 
cells can be similarly detected in many inflammatory skin 
diseases as well as in close proximity of skin cancers occur-
ring in patients with B-cell chronic lymphatic leukaemia 
[122]. One hypothesis suggests that leukaemic cells infil-
trate the skin and drive either Th2 cells or eosinophil and 
basophil activation, e.g. by releasing antibodies against the 
high-affinity immunoglobulin E receptor (FceRI) [123, 124].
An alternative hypothesis is that circulating leukaemic 
cells or the treatment of HMs may cause a persistent skew-
ing of the T-cell repertoire towards the Th2 phenotype, and 
this may favour T-cell recruitment in the skin and activation 
of eosinophils in response to environmental triggers, with 
infiltrating leukaemic cells acting as bystander cells. Both 
scenarios appear possible [105, 124]. The first is supported 
by cases of EDHM worsening during phases of high tumour 
burden, where sometimes important infiltration of the skin 
by neoplastic elements could be detected. The second sce-
nario is supported by cases, the vast majority where EDHM 
occurs while the HM is in partial or complete remission, and 
minimal residual activity of neoplastic cells is expected to 
sustain the Th2 cell response [124].
Treatment of EDHM is at present challenging, owing to 
the lack of evidence-based recommendations [125]. Sys-
temic and topical corticosteroids are considered frontline 
therapies. Immunosuppressants such as methotrexate and 
azathioprine are also effective and allow a reduction in the 
dose of systemic corticosteroids needed to control the dis-
ease and relieve symptoms [103]. One case report supports 
the efficacy of lenalidomide [126].
More intriguingly, two cases described successful 
treatment of EDHM with dupilumab, an anti-IL4 and 
IL-13 receptor monoclonal antibody approved for use in 
atopic dermatitis [127]. The efficacy of dupilumab further 
Fig. 3  a Histopathological 
presentation of eosinophilic 
dermatoses of haematological 
malignancies, showing intense 
dermal oedema and a mixed 
inflammatory infiltrate in 
the dermis with numerous 
eosinophils and flame figures; 
intra-epidermal blistering is also 
visible (haematoxylin and eosin 
staining ×20) and b detail of the 
flame figures (haematoxylin and 
eosin staining ×40)
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strengthens the hypothesis that Th2-cell activation is a cru-
cial step toward EDHM pathology and opens the way for a 
‘targeted’ approach to EDHM treatment.
3.2  T‑Cell Papulosis Associated with B‑Cell 
Malignancies
The term “T-cell papulosis associated with B-cell malignan-
cies” was proposed by Visseaux et al. in 2018, reporting 
38 cases of cutaneous eruptions occurring in patients with 
underlying B-cell lymphoproliferative diseases, especially 
B-cell chronic lymphatic leukaemia. On clinical examina-
tion, these cases were characterised by pruritic papules, vesi-
cles, plaques and nodules, similar to EDHM. Like EDHM, 
the skin rush runs a chronic relapsing course despite treat-
ments; histopathology showed a prominent T-cell infiltra-
tion, sometimes resembling cutaneous T-cell lymphoma 
and, in particular, folliculotropic mycosis fungoides (Fig. 4). 
Despite EDHM, eosinophils were absent in up to 30% of the 
cases [110]. It is our clinical experience (unpublished data) 
that patients with EDHM can present at relapse as “T-cell 
papulosis” or vice versa, suggesting that both diseases are 
“different sides of the same coin”.
3.3  Need for a Unifying Nomenclature
The observation by Visseaux et al. highlights the need to 
find a unifying nomenclature that would help clinicians 
and pathologists to promptly recognise this extremely poly-
morphic spectrum of cutaneous eruptions. As previously 
mentioned, different names have been proposed across the 
years, including exaggerated arthropod bite reactions, insect 
bite-like reactions and eosinophilic dermatoses of myelo-
proliferative diseases [124, 125]. More recently, the acro-
nym “He Remained” (Haematologic Related Malignancy-
Induced Eosinophilic Dermatoses) has been also proposed 
to highlight the pathogenetic link between skin manifesta-
tions and the presence of the HM [128]. A potential con-
sequence of having a large number of names for the same 
condition is that they can generate much confusion among 
clinicians [125]. We respectfully believe that the term “poly-
morphic eruption of haematologic malignancies” may be 
best suited to describe this entity. A proposed classification 
of “polymorphic eruption of haematologic malignancies” is 
explained in Table 2.
Fig. 4  a Clinical presentation of T-cell papulosis associated with 
B-cell malignancies in a patient with B-cell chronic lymphocytic 
leukaemia and b–d microscopic examination showed a prominent 
lymphocytic inflammatory infiltrate with perifollicular distribution 
resembling folliculotropic mycosis fungoides (haematoxylin and 
eosin staining ×20)
Table 2  Classification of polymorphic eruption of haematological malignancy
Eosinophilic Lymphocytic
Bullous (bullous pemphigoid-like)
Panniculitis (Wells syndrome-like)
Insect bite-like
Eosinophilic pustular folliculitis (Ofuji disease-like)
T-cell papulosis associated with B-cell malignancies
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4  Autoimmune Blistering Dermatoses
4.1  Paraneoplastic Pemphigus
Paraneoplastic pemphigus is a rare devastating autoimmune 
disorder of the skin and mucosa, which occurs in patients 
with an underlying malignancy, although it has been spo-
radically described even in the absence of tumours [129, 
130]. Paraneoplastic pemphigus can occur in association 
with several types of malignancies. However, the most fre-
quently reported association is with HMs, and in particular, 
non-Hodgkin’s lymphoma, B-cell chronic lymphatic leukae-
mia and Castleman’s disease [131–133]. For a long time, 
PNP has been regarded as a distinct entity within the clinical 
spectrum of pemphigus, as, like ‘classic’ pemphigus sub-
types, it is characterised by suprabasal acantholysis of the 
skin and mucosa due to IgG autoantibodies targeting adhe-
sion proteins involved in keratinocyte-keratinocyte adhesion 
[134, 135]. However, there are several clinical, histologic 
and immunologic features that clearly distinguish PNP from 
other pemphigus forms: mucosal involvement is generally 
more severe and recalcitrant to immunosuppressive treat-
ment; skin lesions vary from superficial to tense blisters, 
resembling pemphigus or BP, respectively, to lesions mim-
icking erythema multiforme, toxic epidermal necrolysis, 
lichen planus and graft vs host disease (Fig. 5). Besides 
acantholysis, PNP shows a lichenoid lymphocytic infiltrate 
along the dermal–epidermal junction by histopathology 
[136, 137].
Serologically, PNP is only rarely associated with IgG 
antibodies against desmoglein 3 and desmoglein 1, which 
are the main antigenic targets of pemphigus vulgaris 
and foliaceus respectively, whereas IgG autoantibodies 
against envoplakin, periplakin and the protease inhibitor, 
alpha-2-macroglobulin-like antigen-1 are more frequently 
detected. Other IgG autoantibodies targeting desmocollins, 
BP180/BP230, and, occasionally, laminin gamma 1 may 
be also detected in PNP sera [138–143]. As a result, PNP 
requires a specific diagnostic approach, e.g. using plakin-
rich substrates, such as a rat’s bladder, instead of human skin 
or a monkey’s esophagus, for indirect immunofluorescence, 
or dedicated enzyme-linked immunosorbent assay kits for 
detecting circulating IgG autoantibodies, the latter still only 
available in highly specialised centres [144, 145].
Finally, PNP is characterised by several systemic auto-
immune phenomena and sometimes lethal complications, 
such as bronchiolitis obliterans, which have led researchers 
to propose the acronym paraneoplastic autoimmune multi-
organ syndrome instead of PNP [136]. Besides bronchiolitis 
obliterans, other systemic manifestations of paraneoplastic 
autoimmune multi-organ syndrome include myasthenia 
gravis, ocular complications, such as corneal ulcerations, 
cicatrizing conjunctivitis, symblepharon, and pterygium, and 
rarely glomerulosclerosis and paraneoplastic neurological 
syndrome [146]. Paraneoplastic autoimmune multi-organ 
syndrome has been rarely described in pediatric patients 
with HMs, in particular, Castleman’s disease tumours 
[147–150].
From a pathogenetic point of view, while in pemphigus 
T-cell activation is of the Th2-cell type and mainly engaged 
in stimulating IgG autoantibody production by autore-
active desmoglein-specific B cells, PNP demonstrates a 
mixed Th1- and Th2-type response as well as an activation 
of CD8+ cytotoxic T cells. These differences may at least 
partly explain the presence of lichen planus-like lesions, as 
well as the fact that anti-B-cell therapies, e.g. rituximab, 
are less effective than in other clinical pemphigus variants 
[151–153]. Skin and mucosal lesions with lichen planus-like 
characteristics, mirroring the Th1-type and cytotoxic T-cell 
response, may present as the predominant clinical feature 
in patients with PNP who have already received substantial 
immunosuppressive treatment, which may lead clinicians to 
overlooking the diagnosis of PNP [154].
Overall, the course of the disease does not strictly fol-
low that of the underlying neoplasm, nonetheless there is 
a general consensus that early treatment of the neoplasm, 
especially in the presence of Castleman’s disease or thy-
moma, followed by rapid immunosuppressive treatment, will 
dampen PNP symptoms [155, 156]. Based on the evidence 
of increased levels of IL-6 in PNP sera and the crucial role 
of IL-6 in Castleman’s disease [157, 158], tocilizumab, a 
Fig. 5  Paraneoplastic pemphi-
gus a with extensive haemor-
rhagic multiform blisters and 
erosions of the trunk and b 
extensive fibrinous erosions of 
the tongue
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monoclonal antibody targeting IL-6, has been successfully 
applied as a treatment for PNP in this context, but seems 
to have limited effect in preventing bronchiolitis obliterans 
[159, 160]. Rituximab, with or without chemotherapy, rep-
resents an effective therapeutic option for PNP [146, 161]; 
thymoma-associated PNP or multi-organ syndrome also 
respond well to rituximab treatment, but a significant pro-
portion of these patients still die as a result of infections and 
sepsis [137].
Paraneoplastic pemphigus is characterised by a high mor-
tality rate (ca. 57%) and most deaths occur within the first 
year after diagnosis. The presence of anti-envoplakin anti-
bodies, a toxic epidermal necrolysis-like clinical pattern, a 
BP-like clinical pattern and bronchiolitis obliterans is sig-
nificantly associated with a poor disease outcome [162].
4.2  Autoimmune Bullous Dermatoses Other Than 
Paraneoplastic Pemphigus
Apart from PNP, other autoimmune bullous dermatoses have 
been associated with HMs. As opposed to PNP, autoimmune 
bullous dermatoses occurring in patients with haematologi-
cal disorders do not show any specific clinical or serologic 
features as compared to their counterparts occurring in 
patients without haematological disorders.
With regard to pemphigus, a large population-based study 
identified a significant correlation with lymphoproliferative 
disorders, and in particular B-cell chronic lymphatic leukae-
mia [163]. Likewise, in one meta-analysis study, a signifi-
cant association emerged between BP and HMs, with B-cell 
chronic lymphatic leukaemia as again the most represented 
[164]. In both studies, data were extrapolated by national 
registries or by analysing case series and small cohort stud-
ies, with the obvious limitation of the lack of direct vali-
dation of the diagnosis of pemphigus and BP by immuno-
pathology investigations [165]. A potential bias of these 
studies might be the overestimation of these associations 
because of an incorrect diagnosis. While this risk is low for 
pemphigus, it may be considerably higher for BP, given its 
clinical and pathological overlap with EDHM, which, not by 
chance, occurs preferentially in patients with B-cell chronic 
lymphatic leukaemia. Collectively, these findings highlight 
the need for prospective studies to further validate the asso-
ciation between HMs and both pemphigus and BP, as well 
as the importance of referring patients with haematological 
disorders with suspected autoimmune bullous dermatoses to 
specialised centres, where the diagnosis can be confirmed by 
appropriate immunopathology parameters.
The association between HMs and subepidermal autoim-
mune bullous dermatoses other than BP mostly relies on sin-
gle case reports or small series, and almost always involves 
lymphoproliferative disorders. Worth mentioning are cases 
of linear IgA bullous dermatosis associated with B-cell 
chronic lymphatic leukaemia, acute lymphoblastic leukae-
mia and Hodgkin’s lymphoma [166–169]; epidermolysis 
bullosa acquisita with multiple myeloma, mantle cell lym-
phoma and B-cell chronic lymphatic leukaemia [170–174]; 
laminin 332-type mucous membrane pemphigoid with non-
Hodgkin’s lymphoma; and dermatitis herpetiformis with 
non-Hodgkin’s lymphoma of the gastrointestinal tract [175].
5  Miscellaneous
5.1  Cutaneous Vasculitis
Cutaneous vasculitis is characterised by inflammation, dam-
age and destruction of blood vessels of different sizes [176]. 
Cutaneous vasculitis is a quite common disease with an esti-
mated incidence of 39.6/59.8 new cases/million persons/
year. Most cases are related to drugs (20%), infections (22%) 
and connective tissue diseases (12%), while 5% of cutaneous 
vasculitis occur in patients with underlying malignancies 
[177–181]. Such cases are classified as paraneoplastic vas-
culitis. Most of these patients have an underling HM (90%), 
such as chronic myelomonocytic leukaemia, non-Hodgkin’s 
lymphoma, Hodgkin’s disease, B-cell chronic lymphatic 
leukaemia, and multiple myeloma [176, 178, 182, 183]; 
whereas, paraneoplastic cutaneous vasculitis rarely occurs 
in patients with solid tumours (10% of cases), the most com-
mon being renal, breast and lung carcinomas [184–186].
Paraneoplastic cutaneous vasculitis usually presents 
simultaneously with the associated haematological disease. 
It shows similar clinical features of non-malignancy-related 
cutaneous vasculitis, including palpable purpura, ulcers and 
urticarial vasculitis, with a prominent involvement of the 
lower limbs (Fig. 6) [187, 188]. However, paraneoplastic 
cutaneous vasculitis tends to last longer than non-malig-
nancy-related cutaneous vasculitis and is less responsive to 
glucocorticoid or immunosuppressive treatment. Systemic 
symptoms such as fever, arthralgia, general malaise and 
renal involvement may also occur. By histopathology, the 
usual clues include, like classic cutaneous vasculitis, acute 
necrotising inflammation of the small vessels, leukocyte 
perivascular infiltration, nuclear dust and fibrinoid necro-
sis of wall vessels [189]. As we previously described for 
EDHM, leukaemic cells, especially in cutaneous vasculitis 
associated with chronic and acute lymphatic leukaemia, may 
be observed within the perivascular inflammatory infiltrate. 
This may pose a relevant diagnostic challenge to leukaemic 
vasculitis, which is a rare presentation of leukaemia cutis. 
Distinguishing between both entities is of crucial impor-
tance because leukaemic vasculitis is associated with a poor 
prognosis, reflecting the aggressive biological behaviour of 
the associated blood disorder [190–192]. The pathogenesis 
of cutaneous vasculitis in the setting of an HM remains far 
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less clear until now. One possible hypothesis is that neo-
plastic B cells produce antibodies that may form circulating 
immune complexes or rather react directly with endothelial 
antigens in the skin [193]. Of note, HMs augment blood vis-
cosity, which can impair the clearance of normally produced 
immune complexes, and lead to their accumulation on small 
blood vessels [178, 184, 194–196].
It should be also remembered that, besides cutaneous vas-
culitis, HMs can induce a broad spectrum of systemic vascu-
litis, which can present with a secondary involvement of the 
skin, including giant-cell arteritis, large- and medium-vessel 
vasculitis, anti-neutrophil cytoplasmic antibody-associated 
vasculitis and Behçet’s disease [192, 197–202].
5.2  Connective Tissue Diseases
There is a mutual relationship between connective tissue dis-
eases and HMs. On the one hand, patients with a long-term 
history of connective tissue diseases including lupus erythe-
matosus (LE), Sjogren’s syndrome and systemic sclerosis 
demonstrate an increased risk of HMs, with special regard 
to B-cell lymphoma [203–206]. In patients with systemic 
LE, the closest association is with diffuse large B-cell lym-
phoma [207]. On the other hand, marginal zone lymphomas 
and those associated with mucosal-associated lymphoid-
tissue lymphomas are the predominant subtypes observed 
in patients with Sjogren’s syndrome, where the incidence 
is up to 44-fold higher than the general population [208, 
209]. The pathogenesis of B-cell neoplasms in patients with 
connective tissue diseases is likely multifactorial, including 
some shared genetic/environmental factors, chronic inflam-
mation, long-term immunosuppression and persistent high 
levels of cytokines such as IL-6, BAFF, APRIL and Blc2, 
which are involved in both autoimmune disease and lym-
phomagenesis, and, for systemic LE, Epstein–Barr virus 
infection [204, 207].
However, connective tissue diseases can rarely occur as a 
paraneoplastic manifestation of an HM. With regard to the 
various forms of cutaneous LE, subacute cutaneous LE is the 
most frequently reported as a paraneoplastic phenomenon, 
but only a few cases of paraneoplastic subacute cutaneous 
LE have been reported in patients with underlying HMs, 
including acute myeloid leukaemia and Hodgkin’s lym-
phoma [210, 211]. Likewise, only sporadic cases do exist 
about localised or systemic scleroderma as a paraneoplastic 
manifestation of HMs [212].
Dermatomyositis is widely regarded as facultative 
paraneoplastic dermatosis. Dermatomyositis is a complex 
multi-system disease primarily affecting the proximal 
muscles and the skin. Characteristic skin manifestations 
include a heliotrope rash (Fig. 7a), shawl and holster signs, 
Gottron’s papules and erythroderma. Malignancies occur in 
13–42% of patients with dermatomyositis, with the highest 
risk during the first and second year after diagnosis [213]. 
Although most of the cases of malignancy-associated 
dermatomyositis occur in patients with solid tumours, both 
classic and amyopathic dermatomyositis have been shown to 
rarely occur in patients with HMs, including non-Hodgkin’s 
lymphomas, Hodgkin’s disease, myeloid leukaemia and 
myelodysplastic syndromes [214–217]. The presence of 
erythroderma in dermatomyositis is a clinical hallmark 
of malignancy, especially of lymphoid origin [213]. In 
one study, HM-associated dermatomyositis demonstrated 
a poor prognosis, with only half of the patients still alive 
after 5 years. In that study, joint and lung involvement 
and anti-Jo1 antibodies were less commonly exhibited 
by the patients, suggesting that anti-synthetase syndrome 
may be a protective factor against HMs in patients with 
dermatomyositis [215].
It should be also remembered that dermatomyositis-like 
eruptions can be observed in patients with chronic myelo-
proliferative diseases treated with hydroxyurea [218, 219]. 
Flagellate erythema, an uncommon sign of dermatomyositis, 
can be also observed in patients receiving bleomycin-based 
Fig. 6  Palpable purpura consistent with cutaneous leukocytoclastic 
vasculitis in a patient with follicular non-Hodgkin’s lymphoma
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chemotherapeutic regimes, such as in patients with Hodg-
kin’s disease (Fig. 7b) [220].
5.3  Granulomatous Dermatoses
Granulomatous dermatoses comprise a wide range of clini-
cally and aetiologically distinct disorders characterised by a 
granulomatous dermal inflammatory infiltrate predominantly 
composed of histiocytes and macrophages [221, 222]. Albeit 
rare, associations with HMs have been found for various 
granulomatous dermatoses, including granuloma annulare, 
cutaneous sarcoidosis, interstitial granulomatosis and pali-
saded neutrophilic granulomatous dermatitis. While these 
disorders present with different clinical and histological 
presentations, the subtypes of associated HMs are similar, 
and include Hodgkin’s and non-Hodgkin’s lymphoma, myel-
odysplastic syndromes and chronic myelomonocytic leukae-
mia [223–229]. Hodgkin’s lymphoma is a unique example 
of a malignant tumour in which neoplastic cells account for 
less than 10% of the entire tumoural mass, while the remain-
ing 90% is mostly composed of reactive lymphocytes and 
macrophages [230]. Interestingly, patients with Hodgkin’s 
lymphoma can also experience granuloma formation in the 
lung, liver, lymph nodes and spleen, and this may be a con-
sequence of the ability of Reed–Stemberg cells to produce 
cytokines and chemokines that also stimulate recruitment of 
macrophages in peripheral tissues including the skin [231]. 
The association with myelodysplastic syndromes may be 
related to the activation of T-reg cells and the downregula-
tion of T helper-17 cells that are characteristically found 
in the peripheral blood of the patients. The percentage of 
T-reg cells is negatively correlated with the prognosis of 
the myelodysplastic syndrome, and coherently, the appear-
ance of granulomatous dermatoses in these patients may be 
predictive of a poor outcome, sometimes preceding the leu-
kaemic transformation [232–234].
Patients with sarcoidosis harbour a five times higher risk 
of developing lymphoproliferative disorders, in particular 
Hodgkin’s lymphoma. Most of these diseases occur within 
1–2 years of the diagnosis of sarcoidosis and seem to have 
a poor prognosis compared with those occurring in patients 
without sarcoidosis. Remarkably, up to 60% of malignancy-
associated sarcoidosis manifest with cutaneous involvement 
[77, 235–237]. In general, granulomatous dermatoses asso-
ciated with HMs tend to be widespread (Fig. 8) [235] and 
less responsive to steroidal treatments.
6  Discussion and Concluding Remarks
In this review, we show that HMs can lead to several 
immune-mediated phenomena affecting the skin, either 
alone or in the context of systemic diseases. When a der-
matologist is faced with such diseases, one major question 
is whether the cutaneous eruptions harbour any prognostic 
relevance with respect to the underlying HM. In this regard, 
we show that some diseases, such as dermatomyositis or 
granulomatous dermatoses, are clearly linked to a poor 
outcome of the patient. This possibly reflects the fact that 
the emergence of the skin disease is related to unfavourable 
Fig. 7  a Heliotrope rash in a 
patient with dermatomyositis 
who developed non-Hodgkin’s 
lymphoma 2 years after the 
diagnosis and b flagellate 
erythema involving the upper 
arms in a young boy with 
Hodgkin’s lymphoma receiving 
a bleomycin-containing regimen
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immunological alterations associated with the blood disor-
der, as observed for granulomatous dermatoses in the con-
text of myelodysplastic syndromes. In other cases, such as 
PNP, the appearance of the skin disease may be unrelated to 
the biological behaviour of the associated malignancies, but 
carries an increased risk of death in the short term, owing to 
a potentially life-threatening course of the dermatosis itself. 
For other diseases, such as EDHM or ND, the prognostic 
meaning remains to be elucidated.
Based on the temporal appearance of the skin complica-
tions, we can distinguish at least two groups: diseases that 
parallel the clinical course of the HM and diseases that do 
not. One example of the first group is cutaneous vasculi-
tis. Several cases in the literature indicate that cutaneous 
vasculitis usually resolves upon chemotherapy or chemo-
immunotherapy of the associated HM, while recurrence of 
the skin lesions is usually associated with relapse of the HM 
[183, 238, 239]. By contrast, examples of the second group 
include autoimmune bullous dermatoses and PNP, and the 
vast majority of the cases of HM-associated neutrophilic 
and eosinophilic dermatoses. For these disorders, chemo-
therapy may not be a feasible approach; unfortunately, their 
treatment still relies on the use of systemic and topical cor-
ticosteroids and immunosuppressive agents. It should be 
noted that patients with HMs represent a particularly frag-
ile patient population because of an elevated risk of seri-
ous infections. As a result, trying to selectively target the 
immune pathways leading to a specific skin manifestation is 
of crucial importance. For autoantibody-mediated diseases, 
such as PNP and autoimmune bullous dermatoses, rituximab 
and novel anti-B-cell-targeted therapies, including the Bru-
ton tyrosine kinase inhibitor, represent effective strategies 
and target both self-reactive and neoplastic B cells [240].
Another feasible approach could be the use of intravenous 
immunoglobulins, which have shown remarkable efficacy in 
autoimmune bullous dermatoses and dermatomyositis and 
some data exist on the potential benefit for ND [241, 242]. 
Remarkably, they are also used in the haematological set-
ting to replace the pool of circulating immunoglobulins in 
patients with chemotherapy-induced hypogammaglobuline-
mia [243].
Finally, we show that IL-4 inhibitors hold major promise 
as a targeted therapeutic approach in patients with EDHM, 
with an acceptable safety profile owing to a limited impair-
ment of the immune system [127]. There is a prevailing 
sentiment that targeting the cytokine milieu of the tumour 
microenvironment may increase the efficacy of tumour-
directed therapies. For example, experimental evidence 
supports targeting the IL-1-related pathways to augment 
the efficacy of tyrosine kinase inhibitors in patients with 
chronic myeloid leukaemia [6]. Likewise, IL-17 has been 
shown to support the growth of tumoural cells in Hodgkin’s 
lymphoma and B-cell chronic lymphatic leukaemia, and 
promote resistance to chemotherapy in patients with acute 
leukaemia, suggesting that patients would likely benefit from 
IL-17-directed therapies [19–21]. Studies in this direction 
provide an exciting opportunity also for dermatologists, as 
they pave the way for using a therapeutic approach that, 
at the same time, may target the autoimmune disease and 
interfere with the local environment that promotes tumour 
expansion.
We would like to highlight that, besides the diseases dis-
cussed herein, patients with HM treated with haematopoi-
etic allogenic stem cell transplantation may experience a 
plethora of skin diseases with an immune-mediate pathogen-
esis, which, however, do not depend on the HM but rather 
on the immune system of the donor that reacts against the 
antigens of the recipient. These manifestations are collec-
tively referred to as ‘graft vs host disease’. Skin involvement 
is often the earliest sign of graft vs host disease. Lesions 
vary from maculopapular or morbilliform rush and severe 
toxic epidermolysis-like (Fig. 9a) mucocutaneous eruptions 
in acute graft vs host disease, and from lichen-planus-like 
(Fig. 9b) to scleroderma-like eruptions in chronic graft vs 
host disease [23, 244, 245]. We believe that extensive dis-
cussion of this condition is beyond the scope of the present 
work, and may be addressed in a separate review.
To conclude, exploring the molecular mechanisms behind 
the interaction between neoplastic cells and the immune 
system is paramount to develop a targeted approach to 
the management of immune-mediated diseases of the skin 
associated with HMs. We also encourage epidemiological 
Fig. 8  a, b Widespread annular 
granuloma in a female patient 
with chronic myelomonocytic 
leukaemia
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studies aimed at assessing the impact of these complica-
tions in patients with haematological disorders to identify 
underlying risk factors and eventually evaluate their possible 
prognostic significance.
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